Delivery Order SPE2DB24D2003-SPE2DB25FXLJ8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $5,533.31 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $36,245.57 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order was placed under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on...
- The Defense Logistics Agency awarded a delivery order totaling $40,340.72 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,548.16 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The order was placed to...
- The Defense Logistics Agency awarded a delivery order valued at $26,053.21 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with a completion date of August 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $50,771.82 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-unit supply) on August 11, 2025, with a completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,608.50 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract is performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 tablets per unit. This firm fixed price delivery order, valued at $16,263.11, represents a non-competitive set-aside award and is scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLJ8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $33,016.79 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price contract represents a non-compete award and is performed at the awardee's location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationship with the Defense Logistics Agency to supply pharmaceutical products to federal military and healthcare systems. This award is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply medications, vaccines, and medical commodities to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in fulfilling competitive pharmaceutical procurement requirements across diverse therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.0k | 8/5/25 |